KLA Corporation — 7.75/10

KLA Corporation is the dominant pure-play in semiconductor process control — the inspection and metrology ("the eyes of the fab") that find defects and measure critical dimensions during chip manufacturing. Roughly 90% of revenue comes from process control, where KLA holds ~55-60% of the overall inspection/metrology market and ~75-80%+ in the highest-value patterned-wafer and reticle inspection niches — roughly seven times its nearest competitor, with share up ~360bps since 2021. The franchise rides the AI/leading-edge fab build-out: rising process-control intensity at advanced nodes, HBM/DRAM, and advanced packaging. Revenue re-accelerated to +11.5% YoY in CQ1'26 after decelerating through CY2025, on a ~15% five-year revenue CAGR, a ~23% non-GAAP EPS CAGR, a ~18% FCF CAGR, GAAP operating margin +860bps YoY, and a diluted share count down ~14% over five years.

The core of the thesis: KLAC is a textbook market leader in a growing theme. It clears the oligopoly gate decisively, generates positive and growing FCF, and has a Wallace/Higgins management team with a 100% (8/8) hit rate on quantified forward commitments. What holds the composite to 7.75 rather than the high-8s is the back half of the scorecard combined with a trajectory-nuanced financial leg: revenue growth decelerated hard through CY2025 before re-accelerating, non-GAAP operating margin is ~160bps off peak with gross margin structurally capped near 62%, and the latest-quarter FCF was lumpy/down 37% YoY (Financials 7/10); the management-vs-street divergence is real but partly priced (Sentiment 6/10); and the risk set-up is mixed — China ~mid-to-high-20% of revenue (2.5x the 10% threshold, though declining from a ~41% 2024 peak) under a live US export-control regime, at an at-peer ~36-38x forward P/E with no discount cushion (Risks 5/10).

A near-monopoly franchise compounder with 9/10 thematic exposure and 9/10 management attached to a high-quality (7/10) financial profile. KLAC holds ~55-60% of the overall semiconductor process-control market and ~75-80%+ in patterned-wafer and reticle inspection — roughly 7x its nearest competitor, with share still expanding — riding the AI/leading-edge, advanced-packaging, and HBM-intensity super-cycle. Revenue re-accelerated to +11.5% YoY (CQ1'26) on a ~15% 5yr revenue CAGR, ~23% non-GAAP EPS CAGR, and ~18% FCF CAGR, with GAAP operating margin +860bps YoY and a share count down ~14% over five years — delivered by a Wallace/Higgins team that hit 100% (8/8) of its quantified forward commitments. It clears all three quality gates decisively and scores 7.75/10 — BUY.

Quality gate: PASS (0 NOs). Oligopoly YES. Growing FCF YES. Management track record YES. No composite cap applies. The fundamental spine (thematic 9, management 9, financials 7) is well-earned.

What holds the composite below the high-8s is the combination of a trajectory-nuanced financial leg (revenue deceleration through CY2025, non-GAAP operating margin ~160bps off peak, a ~62% gross-margin cap, and a lumpy latest-quarter FCF — Financials 7/10) with the back half of the scorecard: (1) the management-vs-street divergence is real but partly priced, with insiders net-selling and consensus Buy-tilted (Sentiment 6/10), and (2) a mixed risk set-up — China ~mid-to-high-20% of revenue under a live export-control overhang, at an at-peer ~36-38x forward P/E (Risks 5/10).

KLAC is close to the textbook dominant-leader-in-a-secular-theme profile the framework prizes. The oligopoly position is not merely co-leadership; it is a near-monopoly in the segment that matters — ~90% of revenue from process control at ~55-60% overall share (~75-80%+ in patterned-wafer/reticle inspection) with extreme switching costs (decades of defect-library/algorithm data, installed base, a fast-growing services attach, and multi-year yield re-qualification) that make 12-month replacement impossible. KLAC is a price-setter on value/cost-of-ownership, not a price-taker.

The financial trajectory is the nuance, not a flaw. Revenue YoY decelerated from a ~24-30% peak into single digits through CY2025 before re-accelerating to +11.5% in the most recent quarter, non-GAAP operating margin has slid ~160bps off its 44.2% peak, gross margin is structurally capped near 62% by DRAM-component costs and tariffs, and reported FCF was lumpy/down 37% YoY in the latest print on working-capital timing. With management raising CY2026 to high-teens revenue growth and SPC systems guided >20%, the slope looks to be inflecting back up — supportive of the high-quality, above-anchor score.

The entry, not the business, is the debate. There is a genuine management-vs-street divergence (DRAM/HBM intensity stepping toward logic-like levels; KLAC out-growing a market the street models in-line), but it is partly priced: consensus is Buy-tilted with targets above current, insiders are net sellers with zero open-market buying, and the stock is framed as a consensus AI long. The risk leg is the offsetting drag — China ~mid-to-high-20% of revenue (2.5x the 10% threshold, though declining from a ~41% 2024 peak) sits under a live, unpredictable US export-control regime, and valuation on forward P/E (~36-38x) is roughly at the semicap peer average with no discount cushion. An imminent FQ4 FY2026 print (late-July 2026) is the near-term confirm/break on the deceleration-to-reacceleration call.